

માલિક, મુદ્રક, પ્રકાશક : હાર્ડિક એમ. દેસાઈ ● તંત્રી : નાગેન્દ્રકુમાર એચ.આ ● વર્ષ : ૧૫ ● અંક : ૩૧૭ ● તા. ૬-૮-૨૦૨૪, શુક્રવાર ● પાનાઃ ૮ ● કિંમત : રૂ.૧/-
● કાર્યાલય :-બી-૨૦૮, તિલક એવન્દ્યુ, આયુર્વેદિક કોલેજ પાસે, ગ્રિલોકનગર, પાણીગેટ, વડોદરા ● મો.૯૮૦૮૦ ૨૬૭૪૪ ● E-mail : hardik_bindu@yahoo.com

કેન્દ્રીય મંત્રી કિરેન રિજિજુએ લોકસમામાં વક્ફ એક્ટમાં સુધારો કરવા માટેનું બિલ ૨૪ કૃપ્ય

નવી દિલ્હી, તા.૮
 સંસદમાં સરકાર તરફથી આજે
 વક્ફ બોર્ડમાં સુધારાની માગ કરતું
 બિલ રજૂ કરવામાં આવ્યું છે. સંસદીય
 કાર્ય અને લઘુમતી બાબતોના મંત્રી
 ડિરેન રિજિજુ દારા વક્ફ એકટ
 ૧૯૮૫માં સુધારા માટે
 વક્ફ (સુધારા) બિલ ૨૦૨૪ અને
 મુસ્લિમ વક્ફ એકટ ૧૯૨૭ને
 સમાન કરવા માટે મુસ્લિમ વક્ફ
 (રિપીલ) બિલ ૨૦૨૪ લોકસભામાં
 રજૂ કરાયું. તેના પર સંસદમાં
 સત્તાપક અને વિપક્ષ વચ્ચે ચર્ચા
 કરવામાં આવી હતી.
 ડિરેન રિજિજુને કહ્યું કે અમે
 પ્રસ્તાવ મૂકીએ છીએ કે વક્ફમાં
 સુધારા અંગેનું બિલ જોઈન્ટ પાલમિન્ટ
 કમિટીને મોકલી દેવામાં આવે. તેના
 પર સ્પીકરે કહ્યું કે હાં અમે જલદી જ
 સમિતિ બનાવીશું. અસહૃદીન
 ઓવેસીએ આ મામલે ડિવિઝનની
 માગ કરી હતી. જેની સામે સ્પીકરે

કહું કે તેના પર રિવિઝન કેમ માગો છો? ત્યારાબાદ ઓવેસીએ કહું કે અમે તો શરૂથી રિવિઝનની માગ કરી રહ્યા છીએ.

કેન્દ્ર સરકાર વતી કિરેન રિજિઝુએ કહું કે અમે ભાગીશું નહીં. આ બિલ અહીં પાસ કરી દો. તેના પછી તેમાં જે પણ સ્કૂટિની કરવી હોય અમે તેના માટે તૈયાર છીએ. આ બિલ તમે સંયુક્ત સંસદીય સમિતિને મોકલી દો. દરેક પક્ષના સભ્યોને એ

ભિત્તિમાં સામેલ કરો, જે પણ સુટ્ટિની
રવી હોય તેના માટે અમે તૈયાર
કોએ. આ સાથે કિરેન રિજિઝુએ
સ્ટ્રિમ વક્ફ રિપીલ બિલ રજૂ કર્યુ
તું.
એવું જાણવા મળ્યું છે કે જે હેતુ
માટે ૧૮૫૫નો વક્ફ સુધારો
જાવવામાં આઓ હતો તે હેતુ પૂરો
ઈ રહ્યો નથી. તેમાં ઘણી ખામીઓ
જાવા મળી છે. એ સુધારાથી ઈચ્છા
માણેના લક્ષ્યો પ્રામન થયા એટલે

ખખત રજૂ કરાયા. આ કાયદો
બમ ૧૮૫૪માં લાવવામાં
હતો, ત્યારબાદ તેમાં ઘણા
કરવામાં આવ્યા છે. આજે
સુધારો લાવવા જઈ રહ્યા છીએ
કિંફ એક ટ ૧૮૫૫ છે જેમાં
ઉત્તમાં સુધારો કરવામાં આવ્યો
નને તેમાં એવી જોગવાઈ દાખલ
માં આવી હતી જેના કારણે
આ સુધારો લાવવો પડ્યો છે.
પણ વકફ સુધારામાં જે પણ

વિ
તર
આ
અ
જ
આ
કો
નહ
હિ
છે

ઓવેસીએ કહ્યું કે એક હિન્દુ તમે દીકરી કે દીકરાને તમારી સંપત્તિ આપી શકો છો પણ મુસ્લિમ તરીકે એક તૃતીયાંશ પી શકીએ છીએ. હિન્દુ સંગઠન ગુરુદારા મેનજમેન્ટ કમિટીમાં અન્ય ધર્મની વ્યક્તિ સામેલ થતી તો વક્ફમાં કેમ? આ બિલ -મુસ્લિમો વચ્ચે ભેદભાવ કરે ક્ષે પ્રોપર્ટી પલિક પ્રોપર્ટી નથી. આ સરકાર દરગાહ અને અન્ય સંપત્તિઓ લઈ લેવા માગે છે. સરકાર કહે છે કે અમે મહિલાઓને આપી રહ્યા છીએ. અમને વિશ્વાસ છે કે તમે બિલડિંગ્સ બાનો અને જક્કિયા જીકરીને સભ્ય બનાવશો. સત્તા પક્ષ સામે નિશાન તાકતાં અખિલેશ કહ્યું કે તમે દેશને વિભાજિત કરવાનું કામ કરી રહ્યા છો. તમે મુસ્લિમોના હુશ્મન છો.



વડાપ્રધાન નરેન્દ્ર મોદીની પ્રેરણા અને માર્ગદર્શનમાં સમગ્ર દેશમાં ૮મી થી ૧૫મી ઓગસ્ટ દરમિયાન હર ઘર તિરંગા અભિયાન યોજાઈ રહ્યું છે. મુખ્ય મંત્રી ભૂપેન્દ્ર પટેલ આજે ૮મી ઓગસ્ટ, ગુરુવારે સવારે પોતાના નિવાસ સ્થાનની અગાસ્તીમાં તિરંગો લહેરાવી ને આ અભિયાનમાં સ્વયં સહભાગી થયા છે અને રાજ્યમાં હર ઘર તિરંગા અભિયાનનો તેમણે પ્રારંભ કરાયો છે.

સતત ઈમી વાર રેપો રેટમાં કોઈ ફેરફાર નહીં, દ.૪૦ પર યથાવત રાખ્યો

नवी दिल्ली, ता.८
भारतीय रिजर्व बँक (RBI) ए
आजे केंट पोलिसीमां लीपिला
निझयोनी जाहेरात करी छे. आ
वधते पश्च पोलिसी व्याज दरोमां
कोइ फ्रेक्षर करवामां आव्यो नथी.
MPCना हमांथी ४ सञ्चयोमे दरोमां
फ्रेक्षर न करवानी तरफेक्षमां निझय
लीधो उत्तो. अर्थव्यवस्थाना
संदर्भमां, आरबीआईमे 'विध्युतोल
ओफ एकमोडेशन' जाणवी राख्यु छे.
आ निझयनी जाहेरात करता RBI
गवर्नर शक्तिकांत दासे कह्यु के आ
पोलिसी मोंधवारी दरने ४% पर

લાવવા પર આધારેત છે. અમે મોંઘવારી દરના લક્ષ્ય પર રહીએ છીએ. છેલ્લી વખત સેન્ટ્રલ બેંકે ફેલ્યુઆરી ૨૦૨૨ તમાં રેપો રેટમાં ફેરફાર કર્યો હતો. ત્યારથી રેપો રેટ ૬.૫ ટકાના ઉચ્ચ સ્તરે યથાવત છે.

ગયા વર્ષે ભારતે મજબૂત આર્થિક વૃદ્ધિ નોંધવી છે. ભારતીય રિઝર્વ બેંકે પણ છેલ્લી નાણાકીય નીતિ સમિતિની બેઠકમાં નાણાકીય વર્ષ ૨૦૨૪-૨૫ માટે તેના જીવીપી વૃદ્ધિ દરનો અંદાજ ૭ ટકાથી વધારીને ૭.૨ ટકા કર્યો હતો. હા, કુગાવાના મોરચે સ્થિતિ થોડી ચિંતાજનક છે.

સાપોઆઈ (કન્ઝ્ર્યુમર પ્રાઇસ ઇન્ટેક્સ) કુગાવો જૂનમાં ૫.૦૮ ટકાના ચાર મહિનાના ઉચ્ચ સ્તરે પહોંચ્યો હતો. તેવી જ રીતે ખાદ્ય કુગાવો ૮.૩૬ ટકાના ઇ મહિનામાં સર્વોચ્ચ સ્તરે પહોંચ્યો ગયો છે.

બેંક ઓફ બરોડાના ચીફ ઇકોનોમિસ્ટ મદન સબનવીસ આશાવાદી છે કે આરબીઆઈ વ્યાજ દરોમાં કોઈ ફેરફાર નહીં કરે. મોંઘવારી દર આજે પણ ઊંચો છે. આવનારા મહિનામાં તે સંચાલનક રીતે ઘટશે, પરંતુ બેંક ઈફેક્ટને કારણે તે ઊંચો રહેશે. ICRAના મુખ્ય

અથવા સ્થાનક આચકા આવ છે, તો અમે ઓક્ટોબર ૨૦૨૪માં રેપોરેટમાં કાપની અપેક્ષા રાખી શકીએ છીએ. આ પછી ડિસેમ્બર, ૨૦૨૪ અને ફેબ્રુઆરી, ૨૦૨૫માં વ્યાજ દરોમાં ૦.૨૫-૦.૨૫ ટકાનો ઘટાડો થઈ શકે છે.

રેપોરેટ તે વ્યાજ દર છે કે જેના પર ભારતમાં રાષ્ટ્રીયકૃત સરકારી અને ખાનગી ક્ષેત્રની બેંકો RBI પાસેથી નાણાં ઉધીના લે છે. મૌધ્યવારી વધ્યા પછી, દ્વિતીય રેપોરેટમાં વધારો કરે છે જ્યારે કગાવાનો દર

એ છે ત્યારે તન ઘટાડ છે.
રિવર્સ રેપો રેટ એ વ્યાજ દર છે
ના પર જીહેર અને ખાનગી કેતની
કો તેમની થાપણો આરબીઆઈ
પસે રાખે છે. રેપો રેટનો અર્થ એ છે
જ્યારે વ્યાપારી બેંકોને ભંડેળની
પાછતનો સામનો કરવો પડે છે, ત્યારે
ઓ આરબીઆઈ દારા માન્ય
મંકચોરિટીઝ જેમ કે ટ્રેઝરી બિલ્સ
નેમની વૈધાનિક પ્રવાહિતા ગુણોત્તર
ર્થાદીથી (ઉપર) વેચ્યોને ઓક ટિવસ
પાટે આરબીઆઈ પાસેથી લોન લે

સીપી જેવી પાર્ટીઓએ પડા વિરોધ કર્યો છે.
**દ્લીને મળશે રાહત, ગુજરાત-
મહારાષ્ટ્રમાં વરસાદનું એલર્ટ**
નવી દિલ્હી, તા. ૮
દિલ્હી - અન નસી આરમાં
એવે જોરદાર વરસાદ પડ્યો હતો.
ત એવી હતી કે દિલ્હીથી
તીઆરને જોડતા રસ્તાઓ પર
માં ગરકાવ હતા. જેને કારણે

દેખીને મળશે રાહત, ગુજરાત- મહારાષ્ટ્રમાં વરસાદનું એલર્ટ

નવી દિલહી, તા.૮
દિલહી-એ નસીઆરમાં
તારે જોરદાર વરસાદ પડ્યો હતો.
ત એવી હતી કે દિલહીથી
ચીઆરને જોડતા રસ્તાઓ પર
માં ગરકાવ હતા. જેને કારણે
સથી ઘરે જતા સમયે લોકોને
ટ્રાફિક જીમનો સામનો કરવો
હતો. ત્યારે હવામાન વિભાગે
યાની દિલહી માટે ગુરુવારે
જ એલર્ટ આપવામાં આવ્યું છે.
જ ભારે વરસાદને ધ્યનામાં
ના દિલહી પોલીસે એડવાઈરી
ની લીધે

સંભાવના વ્યક્ત કરી છે. હવામાન
વિભાગે આજે ઉત્તરાખંડ, અસમ,
મેધાલય અને સિક્રિકમાં ભારે
વરસાદનું એલર્ટ જાહેર કર્યું છે. તેમજ
રાજ્યસ્થાન, યુપી, હિમાચલ પ્રદેશ,
હરિયાણા, એમ્પી, છતીસગઢ,
મહારાષ્ટ્ર, ગુજરાત, અરુણાચલ
પ્રદેશ, બિહાર, ઓଡિશા, કર્ણાટક
અને ગુજરાતમાં ભારે વરસાદનું
એલર્ટ આપવામાં આવ્યું છે. તેમજ
કેટલાક રાજ્યોમાં ઝડપી પવન
ફૂકવાની સાથે વીજળી પડવાને લઈને
પણ એલર્ટ આપવામાં આવ્યું છે.

“સુધ્દાના જણાવ્યા અનુસાર,
તોની આસપાસ મોનસુન ટર્ફ
છે, તેથી આ અઠવાડિયાના
થી આવતા સમાઈ સુધી
જાણાથી મધ્યમ અને ઘણા
રોમાં ભારે વરસાદ પડી શકે
મેમજ આગામી ૪-૫ દિવસ
માં હળવાથી ભારે વરસાદની

દો કેસમાં

હાઈકોર્ટ નહીં
કોર્ટના આદેશ બાદ હવે તેઓ
અંગારીથી બહાર નહીં આવી શકે.
તોએ આઈ કેસમાં ધરપકડને
ખાયદે જાહેર કરતી અરજી પણ
ફિગાવી દીધી છે. આ સાથે કોર્ટ
ને વચ્ચે વચ્ચે જામીન અરજી
ફિગાવી દીધી છે. હાઈકોર્ટ
ન માટે નીચેલી કોર્ટમાં જવાનું
નથી.
દિલ્હી હાઈકોર્ટ ભુધવારે
(બુધવારી ઓગસ્ટ) એન્ફોર્સમેન્ટ
ન્ટોરેટ (ઇઝ) ને પૂછ્યું કે,
યંત્રી અરવિંદ કેજરીવાલને
વામાં આવેલા જામીનને
રતી અરજીમાં કયું પાસું બાકી

SIGHT
Eycare Hospital

DELAYING EYE TREATMENTS?

NOW THE SOLUTION IS RIGHT AT **SIGHT**.

50K+ Patients	12+ Years
5K+ Cataract	2K+ LASIK

**BEST EYE HOSPITAL FOR CATARACT,
PTERYGIUM & LASIK**

MEDICLAIM & CASHLESS FACILITY AVAILABLE

OPD TIMING	Morning Mon-Sat : 10-12:30 PM	Evening Mon-Fri : 5-7 PM
-----------------------	---	------------------------------------

DR. MANAN SHAH
MS, FICO
CATARACT AND LASIK SURGEON

309, Shlok Infinity Complex, Opposite Vishwakarma Mandir, Chadlodiya, Gota, Ahmedabad - 382481.

FOR APPOINTMENT
63523 80294



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

BROACH LIFECARE HOSPITAL LIMITED

Corporate Identification Number: U86100GJ2023PLC140499

Our Company was incorporated as "Broach Lifecare Hospital Private Limited" pursuant to a certificate of incorporation bearing CIN U86100GJ2023PTC140499 dated April 25, 2023, issued by the Registrar of Companies, Central Registration Centre. Further, in accordance with the main objects, our Company acquired the proprietorship concern of Dr. Jaykumar Narendra Vyas, our Promoter comprising of the Hospitals i.e. Dr. Vyas's Heart Hospital and Dr. Vyas Hospital pursuant to a Business Transfer Agreement date July 17, 2023 ("BTA"). Thereafter, our Company was converted into a public limited company and the name of our Company was consequently changed to 'Broach Lifecare Hospital Limited' bearing CIN U86100GJ2023PLC140499 and a fresh Certificate of Incorporation dated November 7, 2023 issued by Registrar of Companies, Ahmedabad. For further details, please refer to the chapter titled "History and Certain Corporate Matters" beginning on page no. 121 of the Prospectus.

Registered Office: 501, 5th floor, Corporate House, above Bharuch Orthopaedic Hospital, R K Casta, Bharuch Gujarat 392001, India | Tel No: +91 94291 87226; | Email Id: info@maplehospital.in; | Website: www.maplehospital.in | Contact Person: Swati Sharma, Company Secretary & Compliance Officer

THE PROMOTERS OF THE COMPANY ARE DR. JAYKUMAR NARENDRA VYAS, DR. SHACHI JAYKUMAR VYAS AND MRS. DHYUTI KRUPESH JOSHI

THE ISSUE

INITIAL PUBLIC ISSUE OF 16,08,000* EQUITY SHARES OF FACE VALUE ₹ 10/- EACH ("EQUITY SHARES") OF BROACH LIFECARE HOSPITAL LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 25 PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ 15 PER EQUITY SHARE) ("ISSUE PRICE"), AGGRAGATING TO ₹ 402.00 LAKHS (THE "ISSUE"). 84,000 EQUITY SHARES AGGRAGATING TO ₹ 21.00 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 15,24,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ 25 PER EQUITY SHARE AGGRAGATING TO ₹ 381.00 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.49 % AND 25.11 % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 245 OF THE PROSPECTUS.

*Subject to finalisation of basis of allotment

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10.00/- EACH AND THE ISSUE PRICE IS ₹ 25/- PER EQUITY SHARE

THE ISSUE PRICE IS 2.50 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THIS ISSUE IS BEING MADE THROUGH FIXED PRICE PROCESS IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 ("SEBI ICDR REGULATIONS") AS AMENDED AND RULE 19(2)(B)(I) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED (THE "SCR"), THIS ISSUE HAS BEEN MADE FOR AT LEAST 25.00% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "ISSUE PROCEDURE" BEGINNING ON PAGE 256 OF THE PROSPECTUS. A COPY OF THE PROSPECTUS IS FILED WITH THE REGISTRAR OF COMPANIES IN ACCORDANCE WITH SECTION 26 OF THE COMPANIES ACT, 2013.

MINIMUM APPLICATION OF 6000 EQUITY SHARES AND IN MULTIPLES OF 6000 EQUITY SHARES THEREAFTER

DISCLAIMER: IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST RELY ON THE INFORMATION INCLUDED IN THE PROSPECTUS AND THE TERMS OF ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

ISSUE PROGRAMME

ISSUE OPENS ON: TUESDAY, AUGUST 13, 2024

ISSUE CLOSES ON: FRIDAY, AUGUST 16, 2024

ASBA*	Simple, Safe, Smart way of Application - Make use of it!!!	*Applications Supported by Blocked Amount ("ASBA") is a better way of applying to issues by simply blocking the fund in the bank account. For details, check section on ASBA below.	Mandatory in public issue. No cheque will be accepted.
UPI UNITED PAYMENTS INTERFACE	UPI - Now Mandatory in ASBA for Retail Individual Investors (RIIs) Investors are required to ensure that the Bank Account used for bidding is linked to their PAN. UPI - Now available in ASBA for RIIs applying through Registered Brokers, DPs and RTAs. RIIs also have option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. For details on ASBA and UPI process, please refer to the details given in Application Form, Abridged Prospectus, General Information Document for investing in the public issue and also please refer to Section "Issue Procedure" beginning on page 256 of the Prospectus. The process is also available on the website of Lead Manager to the Issue, and the website of BSE Limited ("BSE") and in General Information Document for investing in the Public Issue ("GID"). ASBA Application Forms can be downloaded from the website of BSE Limited ("BSE") and can be obtained from the list of banks that is displayed on the website of the Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. For the list of UPI Apps and Banks live on IPO, please refer to the link www.sebi.gov.in.		

IN TERMS OF THE CIRCULAR NO. CIR/CDF/POLICYCELL/11/2015 DATED NOVEMBER 10, 2015 ALL POTENTIAL INVESTORS PARTICIPATE IN THE ISSUE ONLY THROUGH APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA) PROCESS PROVIDING DETAILS ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS (SCSBs) FOR THE ISSUE. FURTHER PURSUANT TO CIRCULAR BEARING NO. SEBI/HO/CDF/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019 FOR IMPLEMENTATION OF PHASE II FOR UPI FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019 ALL POTENTIAL APPLICANTS ARE REQUIRED TO MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA) PROCESS PROVIDING DETAILS OF THEIR RESPECTIVE ASBA ACCOUNT OR UPI ID (IN CASE OF RIIS), IN WHICH THE CORRESPONDING APPLICATION AMOUNT WILL BE BLOCKED BY THE SCSBs OR UNDER THE UPI MECHANISM, AS APPLICABLE.

FOR MORE DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO THE "ISSUE PROCEDURE" ON PAGE NO 256 OF THE PROSPECTUS.

PROPOSED LISTING

The Equity Shares Issued through the Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME") in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received an In-Principle Approval Letter dated May 24, 2024 from BSE Limited for using its name in the Prospectus for listing of our shares on the BSE SME. For the purpose of this Issue, the Stock Exchange will be the BSE Limited ("BSE").

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI")

Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Issue Document was not filed with SEBI. In terms of the SEBI ICDR Regulations, SEBI shall not issue any observations on the Issue Document. Hence, there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "SEBI Disclaimer Clause" on page 238 of the Prospectus.

DISCLAIMER CLAUSE OF BOMBAY STOCK EXCHANGE LIMITED ("BSE") (STOCK EXCHANGE)

It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the Issue Document has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the Issue Document. The investors are advised to refer to the Issue Document for the full text of the "Disclaimer Clause of BSE" on page 239 of the Prospectus.

RISKS TO INVESTORS

- Our Company has been formed specifically for the purpose of acquisition of the business of Dr. Vyas's Hospital (proprietorship concern of our Promoter i.e., Dr. Jaykumar Narendra Vyas) thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects.
 - We are highly dependent on our doctors and other healthcare professionals, as well as other key personnel and the loss of, or inability to attract or retain, such persons could adversely affect our business and results of operations..
 - We are significantly dependent on our Promoters, Dr. Jaykumar Narendra Vyas, Dr. Shachi Jaykumar Vyas, and any loss of their services could adversely affect our business and results of operations.
 - Our operations are geographically located in Bharuch and Ankleshwar in Gujarat at present and any localized social unrest, natural calamities, etc. could have material adverse effect on business and financial operations.
 - We are a boutique hospital, primarily provide services relating to interventional cardiac services. Any material impact on our earnings from these fields will impact our financial condition and results of operations significantly.
 - We derive a significant portion of our revenues from our tie up arrangements with insurance companies, third party administrators and corporations. The loss of any one or more of our major customers would have a material effect on our business operations and profitability.
 - Delay in receipt of payment from our patients / customers may affect our cash flows, which may, in turn affect our financial condition and results of operations.
 - Our ability to provide affordable healthcare depends on the maintenance of a high volume of patients, occupancy rates, managing operating and effective capital management. Any increase in such costs could adversely affect our business, financial condition and results of operations.
- For further details, please refer chapter titled "Risk Factors" on page no. 22 of the Prospectus.

RISK IN RELATION TO THE FIRST ISSUE

This being the first public issue of our company, there has been no formal market for the securities of our company. The face value of the shares is ₹ 10.00/- per equity share and the Issue Price is 2.50 times of the face value.

AVERAGE COST OF ACQUISITION

The average cost of acquisition per Equity Share to our Promoters as at the date of the Prospectus is:

Name of Promoters	Number of Equity Shares	Average Cost of Acquisition per Equity Share (in ₹)
Dr. Jaykumar Narendra Vyas	38,69,590	11.64
Dr. Shachi Jaykumar Vyas	846	5.71
Mrs. Dhyuti Krupesh Joshi	18	5.56

*As certified by KK Haryani & Co. Chartered Accountants. by way of their certificate dated August 6, 2024.

The Issue Price is Rs. 25.00/- per Equity Share.

DETAILS OF WACA OF ALL SHARES TRANSACTED OVER THE TRAILING EIGHTEEN MONTHS FROM THE DATE OF PROSPECTUS.

The weighted average price at which the equity shares were acquired by our Promoters in the one year preceding the date of the Prospectus.

Period	Weighted Average Cost of Acquisition (in ₹)	Upper end of the Price Band is 'X' times of WACA	Range of Acquisition Lowest Price - Highest Price
Trailing Eighteen months from the date of Prospectus	19.28*	1.30	10-45

*As certified by KK Haryani & Co. Chartered Accountants. by way of their certificate dated August 6, 2024.

The Issue Price is Rs. 25.00/- per Equity Share.

The Issue Price (is determined by our Company in consultation with the Lead Manager) as stated in the chapter titled on "Basis for Issue Price" beginning on page 77 of the Prospectus should not be taken to be indicative of the market price of the equity shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the equity shares of our company nor regarding the price at which the Equity Shares will be traded after listing.

BASIS FOR ISSUE PRICE

1) Basic and Diluted Earnings Per Share (EPS)

Year / Period ended	Basic EPS and Diluted EPS	Weights
March 31, 2021	NA	1
March 31, 2022	NA	2
March 31, 2023	NA	3
March 31, 2024	1.92	4
Weightage Average EPS	1.92	

Note:
i. The face value of each Equity Share is ₹ 10.

ii. Basic Earnings and Diluted per share = Profit for the period / Weighted average number of equity shares outstanding during the period/year.

Note - Figure may change due to rounding off

2) Price to Earnings (P/E) ratio in relation to Issue Price ₹ 25/- per Equity Share of ₹ 10.00/- each fully paid up

Particulars	P/E ratio
P/E ratio based on Basic and diluted EPS as at March 31, 2024	13.02
*Industry	
Highest	44.26
Lowest	(14.42)
Average	14.92

* The highest and lowest industry P/E has been considered from the industry peer set provided later in the chapter. The industry average has been calculated as the arithmetic average P/E of the industry peer set disclosed in the chapter. For further details, see "Comparison with Industry peers" on Note 5 of the chapter.

Note - Figure may change due to rounding off

3) Return on Net worth (RoNW)

Return on Net Worth (RoNW) as per restated financial statements

Year Ended	RoNW (%)	Weights
March 31, 2021	39.95%	1
March 31, 2022	20.39%	2
March 31, 2023	6.40%	3
March 31, 2024	12.75%	4
Weighted Average	15.10%	

Note:

- The figures disclosed above are based on the Restated Financial Statement of our Company. Return on Net worth has been calculated as per the following formula:
- 1) Return on Net Worth (%) = Net Profit after tax attributable to owners of the Company, as restated / Net worth as restated as at year end.
- 2) Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weights) for each year/Total of weights.
- 3) Net worth is aggregate value of the paid-up share capital of the Company and other equity, excluding revaluation reserves if any, as per Restated Financial Information.

4) Net Asset Value (NAV)

Particulars	₹ per share

</

Continue From Previous Page...

e) P/E Ratio for the peer has been computed based on the closing market price of respective Equity Shares as on August 5, 2024 sourced from website of Stock Exchange as divided by the Basic/diluted EPS as applicable.

f) RoNW is computed as net profit after tax (excluding comprehensive income), as attributable to the owners of the Company divided by closing net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus (excluding Revaluation Reserves) and as attributable to the owners of the Company.

For further details, please refer chapter titled "Risk Factors" beginning on page 22 of the Prospectus and the financials of the Company including important profitability and return ratios, as set out in the chapter titled "Restated Financial Statements" beginning on page 147 of the Prospectus to have more informed view about the investment proposition.

The Face Value is ₹ 10.00/- per Equity Share and the Issue Price ₹ 25.00/- has been determined by the Issuer in consultation with the Lead Manager and is justified by the company in consultation with the Lead Manager on the basis of above information.

6) The Issue price is 2.50 times of the face value of the Equity Shares

The Issue Price of ₹ 25 per Equity Share has been determined by the Company in consultation with the lead manager on the basis of an assessment of market demand for the Equity Shares through the fixed price issue process and on the basis of qualitative and quantitative factors.

Prospective investors should read the above-mentioned information along with "Risk Factors", "Business Overview", "Management's Discussion and Analysis of Financial Position and Results of Operations" and "Restated Financial Statements" beginning on pages 22, 102, 209 and 147 respectively, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the "Risk Factors" and you may lose all or part of your investments.

7) Key Performance Indicators

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of our Company.

The KPIs disclosed below have been approved and confirmed by a resolution of our Audit Committee dated August 6, 2024 and the Audit Committee has verified and confirmed that the KPIs pertaining to our Company that have been disclosed to investors at any point of time during the three years period prior to the date of the Prospectus have been disclosed in this section and have been subject to verification and certification by Statutory Auditor, Chartered Accountants, pursuant to certificate dated August 6, 2024, which has been included as part of the "Material Contracts and Documents for Inspection" on page 301 of the Prospectus.

The KPIs of our Company have been disclosed in the chapters titled "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations – Key Performance Indicators" on pages 102 and 209 respectively. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" on page 2 of the Prospectus.

Our Company confirms that it shall continue to disclose all the KPIs included in this chapter on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or complete utilisation of the proceeds of the Fresh Issue as disclosed in "Objects of the Issue" on page 70 of the Prospectus or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Key Performance Indicators -

(₹ in Lakhs except for ratios and percentages)

Particulars	Broach Lifecare Hospital Limited for the financial year ended March 31, 2024	Dr. Vyas's Hospital (Sole proprietorship Concern)			Nature of allotment	Nature of consideration	Total consideration (in ₹ lakhs)			
		Three months period ended June 30, 2023*		As at, or for the fiscal year ended, March 31,						
		2023	2022	2021						
Revenue from operations	260.58	62.39	181.57	339.17	366.35					
Growth in Revenue from Operations ⁽¹⁾ (%)	43.51	-	(46.47)	(7.42)	-					
Total income	260.58	68.84	192.49	347.66	380.24					
EBITDA ⁽²⁾	102.61	45.71	87.44	135.68	133.53					
EBITDA Margin ⁽³⁾	39.38	73.27	48.16	40.00	36.45					
PAT	69.76	20.70	13.85	45.91	76.52					
PAT Margin ⁽⁴⁾	26.77	33.18	7.63	13.54	20.89					
*ROE(5)	12.76	8.51	6.40	20.39	39.95					
Capital Employed ⁽⁶⁾	546.92	901.12	809.98	480.55	263.18					
*ROCE ⁽⁷⁾	17.09	4.09	5.77	21.42	44.54					
Debt ⁽⁸⁾	0.00	657.99	593.66	255.41	71.61					
Net Debt ⁽⁹⁾	(7.34)	594.45	573.65	248.36	59.33					
Debt-Equity Ratio ⁽¹⁰⁾	0.00	2.71	2.74	1.13	0.37					
Net Debt-EBITDA Ratio ⁽¹¹⁾	(0.07)	13.00	6.56	1.83	0.44					
Net Tangible Assets ⁽¹²⁾	546.92	243.14	216.33	225.14	191.57					
Monetary Assets ⁽¹³⁾	7.34	63.54	20.01	7.06	12.28					
% of Monetary Assets to Net Tangible Assets ⁽¹⁴⁾	1.34	26.13	9.25	3.14	6.41					
Net Worth ⁽¹⁵⁾	546.92	243.13	216.32	225.14	191.57					
Return on Net Worth ⁽¹⁶⁾	12.76	8.51	6.40	20.39	39.95					
Pre-Tax Operating Profit ⁽¹⁷⁾	93.45	30.40	34.66	62.26	103.59					
Net Asset Value per Equity Share ⁽¹⁸⁾	12.26	N.A.	N.A.	N.A.	N.A.					

As certified by KK Haryani & Co. Chartered Accountants, by way of their certificate dated August 6, 2024.

* Not Annualized

[^] Company was incorporated on April 25, 2023

Notes:

1. Growth in Revenue from Operations (%) is calculated as Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.

2. EBITDA is calculated as the sum of (i) profit before tax and prior period items for the period/year, (ii) depreciation and amortization expenses, and (iii) finance costs.

3. EBITDA Margin is calculated as EBITDA divided by Revenue from Operations.

4. PAT Margin is calculated as profit for the period/year divided by Revenue from Operations.

5. ROE is calculated as profit for the period/year divided by total equity.

6. Capital Employed is calculated as total equity, plus non-current borrowings, plus current borrowing.

7. ROCE is calculated as earnings before interest and taxes divided by Capital Employed.

8. Debt is calculated as the sum of current borrowings and non-current borrowings

9. Net Debt is calculated as total liabilities less cash & cash equivalents and bank balances.

10. Debt-Equity Ratio is calculated as Debt divided by total equity.

11. Net Debt-EBITDA Ratio is calculated as Net Debt divided by EBITDA.

12. Net Tangible Assets is calculated as the sum of all the assets of our Company excluding, right of use assets and other intangible assets as reduced by total liabilities of our Company.

13. Monetary Assets is calculated as cash and cash equivalents and bank balances and excluding bank deposits with remaining maturity of more than twelve months and fixed deposits held as margin money.

14. % of Monetary Assets to Net Tangible Assets is calculated as Monetary Assets divided by Net Tangible Assets, expressed as a percentage.

15. Net Worth is calculated as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

16. Return on Net Worth is calculated as profit for the period/year divided by Net Worth.

17. Pre-Tax Operating Profit is calculated as profit before tax and prior period items for the period/year, excluding other income, finance cost.

18. Net Asset Value per Equity Share is calculated as Net Worth divided by the number of equity shares for the period/year as adjusted for bonus issue. Weighted average number of equity shares is the number of equity shares outstanding at the beginning of the year/period adjusted by the number of equity shares issued during the year/period multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the year/period.

Explanation of KPI Metrics:

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
Growth in Revenue from Operations	Growth in Revenue from Operations provides information regarding the growth of our business for respective periods
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
PAT	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business
Net worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders' funds.
RoCE (%)	RoCE provides how efficiently our Company generates earnings from the capital employed in the business.

8) Comparison of KPIs based on additions or dispositions to our business

Except for acquisition sole proprietorship concern of Dr. Jaykumar Narendra Vyas, our Promoter comprising of the Hospitals i.e. Dr. Vyas's Heart Hospital and Dr. Vyas Hospital pursuant to a Business Transfer Agreement dated July 17, 2023, our Company has not made any additions or dispositions to its business, in the Financial Year ended March 31, 2024.

9) Set forth below are the details of comparison of key performance of indicators with our listed industry peers:

While our listed peers (mentioned below), like us, operate in the same industry and may have similar offerings or end use applications, they derive significant portion of revenue. Our business may be different in terms of differing business models (for example – focus on Business Support Services which might not be an area of focus for our listed peers), different product verticals serviced or focus areas or different geographical presence.

(₹ in Lakhs except otherwise stated)

Particulars	Family Care Hospitals Limited (Formerly known as Scadent Imaging Limited)			KMC Speciality Hospitals (India) Limited			Global Longlife Hospital and Research Limited		
	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2024	March 31, 2023	March 31, 2022
Revenue from operations ⁽¹⁾	4,000.73	4,729.69	4,206.52	17,717.53	15,575.64	13,607.28	1,351.45	2,350.17	3,281.54
Growth in Revenue from Operations ⁽²⁾	(15.41)	12.44	N.A.	13.75	14.47	N.A.	(42.50)	(28.38)	N.A.
EBITDA ⁽³⁾	1,193.61	832.89	861.41	4,738.58	4,131.49	3,717.40	(31.08)	403.61	802.48
EBITDA Margin% ⁽⁴⁾	29.83	17.61	20.48	26.75	26.53	27.32	2.30	17.17	24.45
PAT	1,254.76	525.72	519.88	3,037.93	2,668.84	2,372.58	218.81	182.75	357.39
PAT Margin % ⁽⁵⁾	31.36	11.12	12.36	17.15	17.13	17.44	(16.19)	7.78	10.89
Net Worth ⁽⁶⁾	5,837.25	4,580.97	1,423.97	14,357.97	11,350.21	8,680.31	2593.14	6,428.97	1,696.22
Capital Employed	6,203.12</td								

